Testing JNJ-78934804 for moderate to severe Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with Crohn's disease at least 12 weeks ago, confirmed by endoscopy (a camera test of your bowel) and biopsy (tissue sample)
- Moderate to severe Crohn's disease activity, shown by symptom scores and endoscopy findings
- Previous treatment with at least one standard Crohn's therapy did not work, stopped working, or caused side effects you couldn't tolerate
- No other types of colitis (inflammation of the colon), strictures (narrowed sections of bowel), or current abscesses (pockets of infection)
- No ostomy (surgically created opening) or history of having more than a small section of bowel removed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
This study tests a new drug called JNJ-78934804 to treat ulcerative colitis (inflammation of the colon and rectum) that is moderate to severe and hasn't responded well to standard treatments. The goal is to see if this drug can reduce inflammation and improve symptoms.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.